LEXINGTON, Mass., June 5, 2017 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with a pipeline of
immune checkpoint antibodies and cancer vaccines, today announced
the results from an ongoing Phase 1 dose-escalation trial for its
anti-CTLA-4 antibody, AGEN1884, in patients with advanced solid
malignancies. The results were presented during a poster session at
the 2017 American Society of Clinical Oncology (ASCO) held in
Chicago, IL.
"We continue to advance our anti-CTLA-4 antibody trial, the
antibody is well tolerated and shows early signs of efficacy, with
a partial response observed in an individual patient," commented
Jean-Marie Cuillerot, M.D., Chief Medical Officer. "A robust safety
and tolerability profile and suggestion of clinical activity are
consistent with our plans to combine this molecule with our
anti-PD-1 antibody in the coming months."
Interim analysis of data collected as of May 16th, 2017 for 16 subjects, who
have exhausted all standard of care options, demonstrated an
acceptable safety and tolerability profile for AGEN1884 at the 0.1,
0.3, 1 and 3 mg/kg dose levels. A partial response was observed for
a patient with angiosarcoma at week 33, with a 92% reduction in
tumor volume upon treatment with 0.1 mg/kg of AGEN1884. While
symptoms associated with immune-related adverse events were
present, there were no dose-limiting toxicities reported to
date.
AGEN1884 was developed under a Collaborative Research and
Development Agreement between Ludwig Cancer Research, 4-Antibody AG
and Recepta Biopharma S.A. AGEN1884 is partnered with Recepta
Biopharma S.A. for certain South American rights.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the
discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing a number of combination approaches that leverage a broad
repertoire of antibody therapeutics and proprietary cancer vaccine
platforms. The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is based in Lexington, MA. For more
information, please visit www.agenusbio.com; information that may
be important to investors will be routinely posted on our
website.
Forward Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the Company's
product candidates and clinical trial plans and activities. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Contact:
Agenus Inc.
Michelle Linn,
781-674-4541
michelle.linn@agenusbio.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/agenus-anti-ctla-4-antibody-shows-strong-safety-and-tolerability-300468467.html
SOURCE Agenus Inc.